Acrivon Therapeutics Inc.... (ACRV)
NASDAQ: ACRV
· Real-Time Price · USD
1.36
-0.03 (-2.16%)
At close: Aug 15, 2025, 3:59 PM
1.38
1.10%
After-hours: Aug 15, 2025, 05:51 PM EDT
Acrivon Therapeutics Common Stock Cash Flow Statement
Financials in USD. Fiscal
year is
undefined.
| Fiscal Year | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 |
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 |
Net Income | -21.01M | -19.68M | -22.83M | -22.44M | -18.8M | -16.49M | -19.25M | -14.47M | -13.91M | -12.76M | -8.93M | -9.2M | -5.82M | -7.22M | -4.34M | -2.44M |
Depreciation & Amortization | 162K | 311K | 303K | 251K | 200K | 224K | 149K | 133K | 129K | 125K | 125K | 116K | 78K | 45K | 13K | 9K |
Stock-Based Compensation | 3.93M | 3.79M | 3.71M | 3.67M | 3.57M | 3.34M | 3.06M | 3.23M | 2.69M | 2.65M | 1.65M | 267K | 233K | 40K | 304K | 27K |
Other Working Capital | n/a | -6.66M | 2.35M | 2.3M | 2.91M | -1.54M | 995K | 1.77M | 2.67M | -470K | -1.14M | 2.26M | -1.04M | -1.37M | -163K | -278K |
Other Non-Cash Items | 307K | -112K | -654K | -968K | -842K | -353K | -300K | 198K | 195K | -942K | -328K | 2K | 181K | 178K | 258K | 18K |
Deferred Income Tax | n/a | n/a | n/a | n/a | n/a | n/a | -186K | -742K | -768K | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Change in Working Capital | n/a | -3.85M | 2.12M | 2.16M | 1.97M | -3.81M | 4.17M | 1.84M | 2.56M | -430K | -1.87M | 2.29M | -496K | -1.46M | 141K | 72K |
Operating Cash Flow | -16.61M | -19.54M | -17.36M | -17.32M | -13.9M | -17.08M | -12.37M | -9.81M | -9.11M | -11.36M | -9.35M | -6.52M | -5.82M | -8.42M | -3.63M | -2.31M |
Capital Expenditures | -493K | -58K | -827K | -989K | -137K | -815K | -1.15M | n/a | -112K | -25K | -251K | -426K | -1.07M | -415K | -137K | n/a |
Cash Acquisitions | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -44.69M | 44.69M | n/a | n/a | n/a | n/a |
Purchase of Investments | -15.06M | -20.23M | -34.76M | -5M | -134.83M | -28.34M | -16.58M | -22.98M | n/a | -16.96M | -100.81M | -49.37M | n/a | n/a | n/a | n/a |
Sales Maturities Of Investments | 35M | 39.5M | 50M | 22M | 46.92M | 35M | 38.27M | 24.5M | 19.45M | 26.32M | 6M | 4.67M | n/a | n/a | n/a | n/a |
Other Investing Acitivies | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 44.69M | -44.69M | n/a | n/a | n/a | n/a |
Investing Cash Flow | 19.45M | 19.21M | 14.41M | 16.01M | -88.04M | 5.85M | 20.54M | 1.52M | 19.34M | 9.33M | -95.07M | -45.12M | -1.07M | -415K | -137K | n/a |
Debt Repayment | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Common Stock Repurchased | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Dividend Paid | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Financial Acitivies | -97K | -344K | -653K | -1.2M | -510K | -166K | -1.3M | n/a | n/a | n/a | 101.86M | 11K | -11K | n/a | n/a | 1K |
Financial Cash Flow | -97K | -343K | -647K | -1.5M | 123.35M | -172K | -2.01M | 78K | 379K | n/a | 101.86M | -140K | -11K | n/a | 99.75M | 1K |
Net Cash Flow | 2.74M | -664K | -3.6M | -2.59M | 21.4M | -11.41M | 6.16M | -8.21M | 10.61M | -2.03M | -2.56M | -51.78M | -6.91M | -8.83M | 95.99M | -2.31M |
Free Cash Flow | -17.1M | -19.59M | -18.19M | -18.31M | -14.04M | -17.9M | -13.52M | -9.81M | -9.22M | -11.38M | -9.61M | -6.95M | -6.9M | -8.83M | -3.76M | -2.31M |